№ lp_1_2_37088
File format: docx Character count: 105012 File size: 440 KB
Public summary of a regulatory and reimbursement assessment detailing clinical evidence, comparators, and PBAC considerations for listing dostarlimab for recurrent or advanced dMMR endometrial cancer following platinum-based chemotherapy.
Year: 2022
Country: Australia
Therapeutic area: Oncology
Disease: Endometrial cancer
Biomarker status: Mismatch repair deficient (dMMR)
Medicine name: Dostarlimab
Brand name: Jemperli
Dosage form: Solution concentrate for intravenous infusion
Sponsor: GlaxoSmithKline Australia Pty Ltd
Regulatory body: Pharmaceutical Benefits Advisory Committee
Submission type: Standard Re-entry submission
Requested listing: Section 100
Comparator treatments: Standard of care chemotherapy; pembrolizumab plus lenvatinib; pembrolizumab monotherapy
Clinical trial referenced: GARNET
Approval status: Provisional approval
Indication: Recurrent or advanced endometrial cancer after platinum-containing regimen
Decision context: PBS listing consideration
Period covered: Up to November 2022
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.

Don’t have cryptocurrency yet?

You can still complete your purchase in a few minutes:
  1. Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
  2. In the app, tap Send.
  3. Select network, paste our wallet address.
  4. Send the exact amount shown above.
After sending, paste your TXID (transaction ID) and your email to receive the download link. Need help? Contact support and we’ll guide you step by step.

The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.